Clinical Trials Logo
  1. Home
  2. Left Ventricular Hypertrophy
  3. NCT02221141
  4. Details
NCT02221141 Clinical Trial

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

Left Ventricular Hypertrophy Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02221141
Other study ID # Fabry Disease Cardioscreening
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 2013
Est. completion date December 2022

Study information
Verified date February 2021
Source Centre Hospitalier Universitaire Dinant Godinne - UCL Namur
Contact Laurence Gabriel
Phone +32 81 42 21 11
Email laurence.gabriel@uclouvain.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom. Actually the early diagnosis is important because a treatment exists that can prevent future complications.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - unexplained left ventricular hypertrophy Exclusion Criteria: - isolated septal hypertrophy

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Belgium CHU Dinant-Godinne Yvoir

Sponsors (1)
Lead Sponsor Collaborator
Laurence Gabriel

Country where clinical trial is conducted

Belgium, 

Outcome
Type Measure Description Time frame Safety issue
Primary Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Completed NCT03322319 - Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose) N/A
Completed NCT01951404 - Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Phase 4
Terminated NCT01188369 - Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy Phase 4
Completed NCT00344903 - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort N/A
Completed NCT00518479 - Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression N/A
Completed NCT00001632 - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease N/A
Completed NCT00001534 - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease N/A
Suspended NCT03193073 - Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient N/A
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting NCT05646056 - A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
Completed NCT01455974 - The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients N/A
Active, not recruiting NCT00418041 - Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) N/A
Completed NCT00602004 - Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan N/A
Completed NCT00219141 - Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Phase 3
Completed NCT03666351 - Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Phase 4
Recruiting NCT05730309 - Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy N/A
Not yet recruiting NCT04022330 - Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging N/A
Recruiting NCT06169358 - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy